- Home
- SDHC vs ANIP Comparison
SDHC vs ANIP Comparison
Compare SDHC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- ANIP
- Stock Information
- Founded
- SDHC 2008
- ANIP 2001
- Country
- SDHC United States
- ANIP United States
- Employees
- SDHC N/A
- ANIP N/A
- Industry
- SDHC
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- ANIP Health Care
- Exchange
- SDHC Nasdaq
- ANIP Nasdaq
- Market Cap
- SDHC 1.5B
- ANIP 1.3B
- IPO Year
- SDHC 2024
- ANIP N/A
- Fundamental
- Price
- SDHC $36.68
- ANIP $60.12
- Analyst Decision
- SDHC Hold
- ANIP Buy
- Analyst Count
- SDHC 6
- ANIP 6
- Target Price
- SDHC $32.10
- ANIP $76.40
- AVG Volume (30 Days)
- SDHC 83.2K
- ANIP 252.6K
- Earning Date
- SDHC 11-23-2024
- ANIP 11-06-2024
- Dividend Yield
- SDHC N/A
- ANIP N/A
- EPS Growth
- SDHC N/A
- ANIP N/A
- EPS
- SDHC 7.94
- ANIP 1.18
- Revenue
- SDHC $825,107,000.00
- ANIP $538,953,000.00
- Revenue This Year
- SDHC $24.81
- ANIP $22.23
- Revenue Next Year
- SDHC $23.12
- ANIP $16.84
- P/E Ratio
- SDHC $4.63
- ANIP $50.53
- Revenue Growth
- SDHC 5.85
- ANIP 34.27
- 52 Week Low
- SDHC $20.55
- ANIP $48.20
- 52 Week High
- SDHC $39.50
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- SDHC 50.31
- ANIP 55.58
- Support Level
- SDHC $36.31
- ANIP $54.93
- Resistance Level
- SDHC $38.06
- ANIP $57.74
- Average True Range (ATR)
- SDHC 1.30
- ANIP 1.45
- MACD
- SDHC -0.20
- ANIP 0.39
- Stochastic Oscillator
- SDHC 28.53
- ANIP 90.03
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.